This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Emerging research on RNA biomarkers, AI applications, and genetic mutations shows promise for developing new diagnostic tools for bipolardisorder. Non-pharmacological approaches and combination therapies are emphasized in treatment, with recent FDA approvals for new medications targeting bipolar symptoms.
SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Healthcare professionals should monitor weight and growth in young patients on these medications and consider alternative treatments if adverse effects occur.
1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. The CNPV program, introduced by FDA Commissioner Marty Makary, aims to reduce review times to 1-2 months for eligible applications.
Related Videos Related Content Advertisement July 7th 2025 The Psychiatric Pipeline in Review: Quarter 2, 2025 Leah Kuntz September 27th 2021 Treating ‘Morally Objectionable’ Patients James L.
Ms Barbee has a passion to reduce the stigma around mentalhealth and promoting increased access to mentalhealth care and education of both clinicians and the general public. She has also served as advisory board participant for Supernus Pharmaceuticals and Axsome Therapeutics. Goldberg, MD, and Anita H.
The COMP005 trial is the first phase 3 study of synthetic psilocybin, marking a milestone in psychedelic research for mentalhealth. No unexpected safety issues or imbalance in suicidal ideation were observed between treatment and placebo groups. points (95% CI [-5.7, -1.5]) in change at the primary endpoint.
of patients who were prescribed antipsychotics for their psychiatric illness and had evidence of tardive dyskinesia (TD) had TD recorded properly in their electronic health records, supporting the idea that TD is often underreported and misdiagnosed and, therefore, not treated appropriately.
Stein, MD, MPH, distinguished professor of psychiatry and public health at the University of California San Diego and a Transcend consultant, was equally excited about the designation and its meaning for patients. This Breakthrough Therapy designation enables us to work more closely with the FDA as we prepare to launch our Phase 3 program."
Division of Clinical Pharmacology, Indiana University School of Medicine Updated 2021. Flockhart DA, Thacker D, McDonald C, et al. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Accessed June 11, 2025. Goldberg, MD, and Anita H.
Clark, MD Dr Clark is an outpatient psychiatrist at Prisma Health-Upstate and clinical associate professor at the University of South Carolina School of Medicine, Greenville. When the darkness fades, and the bluebonnets bloom, a lone star will shine, lighting up the skies, to heal Kerr county’s cries.
FDA Indications, Potential Future Indications, and Areas of Investigation for GLP-1 RAs Soon after their introduction, GLP-1 RAs’ significant weight-lowering effects and health benefits in other medical disorders became apparent, with relatively greater metabolic and weight loss benefits reported with newer GLP-1 RAs and dual agonists.
Leah Kuntz October 7th 2021 Blue Light Blockers: A Behavior Therapy for Mania Chris Aiken, MD Kellie Newsome, PMH-NP July 7th 2025 Transformation 2.0: Leah Kuntz October 7th 2021 Blue Light Blockers: A Behavior Therapy for Mania Chris Aiken, MD Kellie Newsome, PMH-NP July 7th 2025 Transformation 2.0:
1 When evaluating patients, Robinson outlines that “we need to evaluate not only the risk of the medication exposure to the mother and the infant, but the very serious consideration of the untreated mental illness and those effects, which can be quite severe.”
A 1989 publication by psychiatry icons Gelenberg et al 8 convincingly demonstrated that for maintenance treatment of patients with bipolardisorder with a serum lithium concentration of 0.4 Comparison of standard and low serum levels of lithium for maintenance treatment of bipolardisorder. mmol/L, there was a 2.6
As the newest cohort in psychiatric training, they are digital natives, accustomed to rapid information retrieval, online simulations, and mentalhealth apps. 9 Another major technological shift in medicine has been the integration of electronic health records (EHRs). 4 Why Is Technology at the Center of the Conversation?
Leah Kuntz August 3rd 2021 Four Myths About Lamotrigine Chris Aiken, MD Kellie Newsome, PMH-NP July 9th 2025 Teaching Psychopharmacology Mike Hennessy Jr July 7th 2025 Transformation 2.0: The GLP-1 RAs as Psychiatric Medications? The GLP-1 RAs as Psychiatric Medications?
She ended the conversation by telling me that I could ask the staff for more sleeping medication if I needed it and that she’d see me the following day. I roomed with a Portuguese woman who was diagnosed with bipolardisorder. I was discharged on December 14, 2021, but remnants of myself are still lingering around the hospital.
McIntyre, MD, FRCPC Key Takeaways Incretin-based treatments, especially GLP-1 RAs, may address comorbidities in mentaldisorders and have direct CNS effects, potentially modifying disease progression. The GLP-1 RAs as Psychiatric Medications? The GLP-1 RAs as Psychiatric Medications? The GLP-1 RAs as Psychiatric Medications?
Prodromal symptoms encompass mood changes such as anxiety, depression , mood swings, sleep issues, irritability, anger, and potential suicidal thoughts. Commonly documented clinical findings of a schizophrenic prodrome include cognitive deficits (memory, attention, and concentration).
Thomas Insel, director of the National Institute of MentalHealth (NIMH) from 2002-2015, acknowledged in 2011, “Whatever we’ve been doing for five decades, it ain’t working. adults now takes an antidepressant”; however, Time continued, “Mentalhealth is getting worse by multiple metrics. As of late 2022, just 31% of U.S.
Siem: Often, the extent to which someone can go low correlates to how high they can go, like with mania in bipolardisorder. But when she came off Clozaril, she struggled to sleep. Normally, she sleeps 10 hours. I think the lack of sleep triggered the mania. Combined with the lack of sleep, it turned into mania.
BRIEF BOOK REVIEWS Popular Books Relevant to MentalHealth Educated: A Memoir Tara Westover; Random House, 2018 352 pages; $12 (hardcover) Reviewed by Edmund S. Could some of the characters meet criteria for bipolardisorder? Posttraumatic stress disorder? Depression? Quite possibly.
Siem: Often, the extent to which someone can go low correlates to how high they can go, like with mania in bipolardisorder. But when she came off Clozaril, she struggled to sleep. Normally, she sleeps 10 hours. I think the lack of sleep triggered the mania. Combined with the lack of sleep, it turned into mania.
Dr. Moffic, a retired psychiatrist, remains an advocate for mentalhealth, addressing issues like climate instability, physician burnout, and xenophobia. SHOW MORE Explore the significance of Juneteenth, its historical context, and the ongoing challenges of truth and equity in mentalhealth care.
Steven Moffic, MD Series | Psychiatric Views on the Daily News Mentalhealth: it is time to do what is needed now or it will be more extensive and expensive later. The rally put together by some of us psychiatrists was unprecedented. I wore my own designed red T-shirt stating, “Make America Sane Again.”
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content